Viridian Therapeutics, Inc.\DE (VRDN) Research & Development (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Research & Development history runs 14 years deep, the most recent figure standing at $77.6 million for Q1 2026.

• On a quarterly basis, Research & Development rose 1.04% year-over-year to $77.6 million in Q1 2026; TTM through Mar 2026 was $260.5 million, a 4.97% decrease from a year earlier, with the FY2025 full-year figure at $338.9 million, up 42.26% from the prior year.
• Research & Development grew to $77.6 million in Q1 2026 per VRDN's latest filing, from $10.0 million in the prior quarter.
• Across five years, Research & Development topped out at $86.6 million in Q2 2025 and bottomed at $5.6 million in Q4 2022.
• The 5-year median for Research & Development is $40.9 million (2024), against an average of $47.2 million.
• Across the five-year window, Research & Development jumped 588.52% in 2023 and sank 86.1% in 2025, its largest moves.
• Year by year, Research & Development stood at $5.6 million in 2022, then soared by 588.52% to $38.6 million in 2023, then surged by 86.63% to $72.0 million in 2024, then sank by 86.1% to $10.0 million in 2025, then surged by 676.31% to $77.6 million in 2026.
• Per Business Quant, the three latest VRDN Research & Development figures stand at $77.6 million (Q1 2026), $10.0 million (Q4 2025), and $86.3 million (Q3 2025).